[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343038-105":59,"doc-detail-343038-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","17-estradiol-in-colorectal-cancer-friend-or-foe","17β-estradiol in colorectal cancer: friend or foe?","","Colorectal cancer (CRC) is a common gastrointestinal malignancy with higher incidence and mortality in men than women, potentially linked to estrogen signaling. Strong evidence indicates 17β-Estradiol (E2) lowers CRC risk in females, yet the conclusion remains debated. E2 can suppress CRC cell proliferation and migration through enhanced DNA mismatch repair, gene-expression modulation, cell-cycle arrest, and reduced migration-factor activity. It may also shape an unfavorable tumor microenvironment by increasing ERβ, dampening inflammation, reversing immunosuppression, and altering gut microbiome composition. In contrast, high oxidative stress, hypoxia, or nutritional deficiency may promote CRC via GPER-mediated non-genomic signaling. This review integrates genomic and non-genomic mechanisms and highlights E2’s dual roles in anticancer activity versus carcinogenesis while suggesting prevention and treatment strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/17-estradiol-in-colorectal-cancer-friend-or-foe/343038/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/17-estradiol-in-colorectal-cancer-friend-or-foe/343038.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are the two opposing roles of 17β-estradiol (E2) in colorectal cancer?","Question",{"text":113,"@type":114},"E2 can reduce CRC risk by inhibiting tumor cell proliferation and migration and by creating a tumor microenvironment unfavorable for CRC growth. Under conditions such as oxidative stress, hypoxia, and nutritional deficiencies, E2 may instead facilitate CRC development through GPER-mediated non-genomic signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Through which mechanisms does E2 exert anticancer effects at the cellular level?",{"text":118,"@type":114},"E2 inhibits CRC cell proliferation and migration by enhancing DNA mismatch repair, modulating key gene expression, inducing cell-cycle arrest, and reducing the activity of migration factors.",{"name":120,"@type":111,"acceptedAnswer":121},"How does E2 influence the tumor microenvironment in CRC?",{"text":122,"@type":114},"E2 promotes an unfavorable tumor microenvironment by stimulating ERβ expression, reducing inflammatory responses, reversing immunosuppression, and altering gut microbiome composition.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343038,1790792234,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Wu et al. Cell Communication and Signaling (2024) 22:367  \n[https://doi.org/10.1186/s12964-024-01745-0](https://doi.org/10.1186/s12964-024-01745-0)  \nCell Communication and Signaling  \nREVIEW Open Access  \n17β-estradiol in colorectal cancer: friend or foe?  \nZihongWu 1*†, Chong Xiao 1,2†, Jiamei Wang 1, Min Zhou3, Fengming You 1,2,4* and Xueke Li 1,2*  \nAbstract  \nColorectal cancer (CRC) is a common gastrointestinal malignancy with higher incidence and mortality rates in men compared to women, potentially due to the effects of estrogen signaling. There is substantial evidence supporting the significant role of 17β-Estradiol (E2) in reducing CRC risk in females, although this perspective remains debated. E2 has been demonstrated to inhibit CRC cell proliferation and migration at the cellular level by enhancing DNA mismatch repair, modulating key gene expression, triggering cell cycle arrest, and reducing activity of migration factors. Furthermore, E2 contributes to promote a tumor microenvironment unfavorable for CRC growth by stimulating ERβ expression, reducing inflammatory responses, reversing immunosuppression, and altering the gut microbiome composition. Conversely, under conditions of high oxidative stress, hypoxia, and nutritional deficiencies, E2 may facilitate CRC development through GPER-mediated non-genomic signaling. E2’s influence on CRC involves the genomic and non-genomic signals mediated by ERβ and GPER, respectively, leading to its dual roles in anticancer activity and carcinogenesis. This review aims to summarize the potential mechanisms by which E2 directly or indirectly impacts CRC development, providing insights into the phenomenon of sexual dimorphism in CRC and suggesting potential strategies for prevention and treatment.  \nKeywords Colorectal cancer, 17β-estradiol, Dual roles, Cellular processes, Tumor microenvironment  \nIntroduction  \nColorectal cancer (CRC) represents a significant public health challenge worldwide, with high rates of morbidity and mortality [1]. Epidemiological studies have shown significant sex differences in CRC incidence and outcomes [2, 3]. From 2015 to 2019, men have shown approximately 30–40% higher annual incidence and mortality rates compared to women, along with slightly lower five-year survival rates [1, 3]. Individuals who have  \n†Zihong Wu and Chong Xiao contributed equally to this work.  \n*Correspondence:  \nFengming You [yfmdoc@163.com](yfmdoc@163.com)  \nXueke Li [2017202040046@whu.edu.cn](2017202040046@whu.edu.cn)  \nFull list of author information is available at the end of the article  \ntaken oral contraceptives or undergone postmenopausal hormone replacement therapy (HRT) have exhibited a 20-40% lower risk of CRC compared to those who have not undergone these treatments [4]. Moreover, postmenopausal patients tend to have lower levels of serum free estradiol and total 17β-estradiol (E2), which correlates with later tumor stagese [4–6]. These clinical findings underscore the protective effect of estrogen, particularly E2, in reducing CRC risk in women. However, the role of E2 in CRC remains controversial. Some studies have found no significant association between E2 levels and CRC risk [7–9], while others suggest that E2 might contribute to malignant progression and poorer outcomes in CRC [10, 11]. Despite most evidence supporting the link between HRT and reduced CRC risk in women, conflicting reports exist, indicating that the protective effect may vary among specific molecular  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unle","cbCaijew1020vucU","https://ap.wps.com/l/cbCaijew1020vucU","pdf",3953011,"English","# Abstract\n# Introduction\n## Sex differences in CRC incidence and outcomes\n## Clinical evidence linking estrogen exposure with CRC risk\n## Controversies regarding E2 and CRC progression\n# E2 biology and signaling pathways\n## Genomic and non-genomic signaling via ERβ and GPER","[{\"question\":\"What are the two opposing roles of 17β-estradiol (E2) in colorectal cancer?\",\"answer\":\"E2 can reduce CRC risk by inhibiting tumor cell proliferation and migration and by creating a tumor microenvironment unfavorable for CRC growth. Under conditions such as oxidative stress, hypoxia, and nutritional deficiencies, E2 may instead facilitate CRC development through GPER-mediated non-genomic signaling.\"},{\"question\":\"Through which mechanisms does E2 exert anticancer effects at the cellular level?\",\"answer\":\"E2 inhibits CRC cell proliferation and migration by enhancing DNA mismatch repair, modulating key gene expression, inducing cell-cycle arrest, and reducing the activity of migration factors.\"},{\"question\":\"How does E2 influence the tumor microenvironment in CRC?\",\"answer\":\"E2 promotes an unfavorable tumor microenvironment by stimulating ERβ expression, reducing inflammatory responses, reversing immunosuppression, and altering gut microbiome composition.\"}]","17β-estradiol in colorectal cancer: friend or foe? | PDF",1790049531,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ac7ce13f170fe5e887eb99974b09c25.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/260564ff3a67010c17b6e62a7f0fc4db.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25cb5013e357acd220db45cdf3b0236c.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/110692d698f5732a23b8080a6854a320.webp",980,1306]